The Middle East & Africa sarcopenia treatment market was valued at US$ 66.59 million in 2022 and is expected to reach US$ 90.55 million by 2030; it is estimated to register a CAGR of 3.9% from 2022 to 2030.
Rising Awareness About Sarcopenia Bolster Middle East & Africa Sarcopenia Treatment Market
The growing awareness of sarcopenia and its negative impact on health presents a significant scope for advancements in the fields of healthcare and geriatric care. Many advocacy groups and organizations are proactively taking steps to raise the awareness of sarcopenia among the masses. These organizations often work with medical professionals to keep the public updated on the various aspects of certain disorders, such as pathogenicity, target patients, prevention, and treatments, along with underlining the value of prompt diagnosis and treatment. In line with OWH's "Stronger than Sarcopenia" campaign, women are urged to discuss sarcopenia with their healthcare providers, followed by undergoing screen for the illness and taking appropriate therapy if required.
Sarcopenia has been included in the curricula of medical schools and training programs for healthcare professionals such as physicians, nurses, and physical therapists. For example, the OWH worked with Medscape Education to create continuing medical education (CME) credits for healthcare professionals, which will better equip them to detect and treat sarcopenia in their patients. Mainstream media has expanded its coverage of sarcopenia to include articles, news stories, and documentaries. Thus, the elevating awareness regarding sarcopenia is likely to bring new growth trends into the sarcopenia treatment market in the coming years.
Middle East & Africa Sarcopenia Treatment Market Overview
The Middle East & Africa sarcopenic treatment market is segmented into Saudi Arabia, the UAE, South Africa, and the Rest of MEA. The UAE and Saudi Arabia are among the most significant contributors to the market due to the rising incidence of orthopedic disorders. Increasing awareness among the large population about the use and benefits of nutritional supplements also benefits the market progress.
An increased risk of sarcopenia in South Africa is associated with the aging population, and inadequate food security and nutrient intake brought on by poverty. The sarcopenia treatment market in this country is anticipated to be driven by a distinct population-specific approach taken by health authorities for the diagnosis, treatment, and prevention of sarcopenia.
Middle East & Africa Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Million)
Middle East & Africa Segmentation
The Middle East & Africa sarcopenia treatment market is categorized into treatment type, distribution channel, and country.
Based on treatment type, the Middle East & Africa is segmented into vitamin D and calcium supplement, protein supplement, vitamin B12 supplement, and others. The vitamin D and calcium supplement segment held the largest Middle East & Africa share in 2022.
In terms of distribution channel, the Middle East & Africa is segmented into pharmacies, retail channels, online channels, and others. The pharmacies segment held the largest Middle East & Africa share in 2022.
By country, the Middle East & Africa is segmented into Saudia Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. South Africa dominated the Middle East & Africa share in 2022.
Abbott Laboratories, Bayer AG, Nestle Health Science SA, Novartis AG, Pfizer Inc, Sanofi SA, Amway Corp, and GSK Plc are some of the leading companies operating in the Middle East & Africa .
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 66.59 Million |
| Market Size by 2030 | US$ 90.55 Million |
| CAGR (2022 - 2030) | 3.9% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2030 |
| Segments Covered |
By Treatment Type
|
| Regions and Countries Covered |
Middle East and Africa
|
| Market leaders and key company profiles |
|
1. Abbott Laboratories
2. Bayer AG
3. Nestle Health Science SA
4. Novartis AG
5. Pfizer Inc
6. Sanofi SA
7. Amway Corp
8. GSK Plc
The Middle East & Africa Sarcopenia Treatment Market is valued at US$ 66.59 Million in 2022, it is projected to reach US$ 90.55 Million by 2030.
As per our report Middle East & Africa Sarcopenia Treatment Market, the market size is valued at US$ 66.59 Million in 2022, projecting it to reach US$ 90.55 Million by 2030. This translates to a CAGR of approximately 3.9% during the forecast period.
The Middle East & Africa Sarcopenia Treatment Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Middle East & Africa Sarcopenia Treatment Market report:
The Middle East & Africa Sarcopenia Treatment Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Middle East & Africa Sarcopenia Treatment Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Middle East & Africa Sarcopenia Treatment Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Middle East & Africa Sarcopenia Treatment Market
